Small-scale Aav Production
Small-scale Aav Production - Related Videos
03:20
Large-Scale Production of High-Capacity Adenoviral Vectors
0 Views •
2026
Source: Ehrke-Schulz, E., et al. Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5. J. Vis. Exp. (2016)This video demonstrates the large-scale amplification of high-capacity adenoviral vectors in suspension-adapted human embryonic kidney cells expressing Cre recombinase for use in gene delivery applications requiring high-titer, helper-free vector preparations.
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
0 Views •
Cited by 9 •
2017
This protocol describes the production of a therapeutic antibody in a mammalian expression system. The methods described include preparation of vector DNA, stable transfection and serum-free adaptation of a human embryonic kidney 293 cell line, set up of large scale cultures and purification using affinity chromatography.
13:36
Synthetic Spider Silk Production on a Laboratory Scale
0 Views •
Cited by 16 •
2012
Despite the outstanding mechanical and biochemical properties of spider silks, this material cannot be harvested in large quantities by conventional means. Here we describe an efficient strategy to spin artificial spider silk fibers, which is an important process for investigators studying spider silk production and their use as next-generation biomaterials.
08:38
Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods
0 Views •
Cited by 14 •
2016
A production protocol is described for the small-scale production of probiotic fermented dairy drink with the aid of a novel bacterial starter culture.
21:55
Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling
0 Views •
Cited by 35 •
2012
We demonstrate the basic technique to molecularly engineer and evolve synthetic Adeno-associated viral (AAV) gene therapy vectors via DNA family shuffling. Moreover, we provide general guidelines and representative examples for selection and analysis of individual chimeric capsids with enhanced properties on target cells in culture or in mice.
FAQs
The plasmid system separates essential functions across complementary components. One plasmid carries the experimental or therapeutic genome, another supplies viral replication and capsid proteins, and helper functions support production in transiently transfected producer cells. Coordinating these inputs allows cells to assemble recombinant particles containing the selected genetic payload without relying on a single multifunctional construct.
Serotype comparison helps determine which capsid variant is most suitable for a planned experiment before committing to larger-scale production. Preparing multiple small-scale vectors creates an efficient way to test alternative vector designs under comparable conditions. In neuroscience, this early comparison can support selection of vectors for studies involving neurons, glial cells, neural circuits, or disease-related genetic manipulations.
Genome titer and quality assessment provide complementary information about the resulting vector preparation. Genome titer measures the amount of vector-associated genetic material, whereas broader quality assessment examines whether the preparation meets the experimental requirements. Considering both readouts helps distinguish a preparation that contains genetic material from one that is adequately suitable for downstream testing.
A typical workflow begins by transiently transfecting producer cells with plasmids encoding the vector genome, replication and capsid proteins, and helper functions. After particle assembly, the material is harvested from the production system, purified, and evaluated for genome titer and quality. These stages connect vector design with a characterized preparation ready for experimental use.
Small-scale production is especially useful during early construct testing, when researchers need information before expanding manufacturing. It supports comparison of experimental genomes and serotypes, identifies promising designs, and enables optimization of the production approach. This staged process can reduce unnecessary investment in larger-scale preparation until a vector has demonstrated sufficient value for continued development.
In neuroscience, characterized AAV preparations can introduce selected genes into neurons and glial cells, creating tools for examining neural circuits and disease mechanisms. The same workflow can support early evaluation of gene-based therapeutic strategies. Small-scale material is therefore valuable for testing whether a construct and vector design are appropriate for the intended neural research question before further scale-up.